Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Oct
28
Today In Oncology
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors
Impact of Digital Breast Tomosynthesis on Invasive Interval Breast Cancer Rate
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo